Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study.
Kerri BeckmannBeth RussellDebra JosephsHans GarmoChristel HaggstromLars HolmbergPär StattinMieke Van HemelrijckJan AdolfssonPublished in: BMC cancer (2019)
Detection bias most likely explains the elevated risk of prostate cancer with prior history of CIDs or use of AIMs, given the higher risk immediately after first CID event and lack of dose response. However, findings for length of time with asthma and dose of inhaled glucocorticoids suggest that asthma may increase risk of prostate cancer through other pathways.